Volume 30 Issue 9, September 2012

Editorial

Will the floodgates open for gene therapy?

In a matter of days, a momentous event will occur: a gene therapy will, for the first time anywhere in the Western hemisphere, be available commercially with full marketing approval.

Editorial 10 Sept 2012

Advertisement
Further confirmation needed

A new mechanism for independently replicating research findings is one of several changes required to improve the quality of the biomedical literature.

Special:

Challenges in irreproducible research
Editorial 10 Sept 2012

Top of page ⤴

News

First gene therapy nears landmark European market authorization

Nuala Moran
News 10 Sept 2012
US funds vaccine centers for biodefense

Michael Eisenstein
News 10 Sept 2012
Bayer acquisition spotlights biopesticides

Jim Kling
News 10 Sept 2012
Regulatory fog lifts on obesity drugs

Aaron Bouchie
News 10 Sept 2012
Amylin's three-party good-bye

Brady Huggett
News 10 Sept 2012
Industry cautiously welcomes Supreme Court decision on healthcare overhaul

Emily Waltz
News 10 Sept 2012
Compulsory license bandwagon gains momentum

Michael Francisco
News 10 Sept 2012
Biotechs opt for alternative floatation strategy

Mark Ratner
News 10 Sept 2012
GSK buys partner Human Genome Sciences

Mark Ratner
News 10 Sept 2012
India's biosimilar regulations

Killugudi Jayaraman
News 10 Sept 2012
Myriad's patents redux

Laura DeFrancesco
News 10 Sept 2012
NIH injects $275 million into undiagnosed diseases and RNA research

Malorye Allison
News 10 Sept 2012
China's key R&D programs behind schedule

Hepeng Jia
News 10 Sept 2012
Around the world in a month

News 10 Sept 2012

Top of page ⤴

Data Page

Drug pipeline: Q212

Laura DeFrancesco
Data Page 10 Sept 2012

Top of page ⤴

News Feature

Patient power

Patient foundations are not only exploring new funding models but also catalyzing translational research, with notable successes. Jim Kling reports.

Jim Kling
News Feature 10 Sept 2012

Top of page ⤴

Bioentrepreneur

How much risk are you prepared to take?

Any faculty member wishing to commercialize a discovery or technology should contemplate the pros and cons of pursuing the entrepreneurial route or licensing to an outside entity.

Mark Van Dyke
Bioentrepreneur 10 Sept 2012

Top of page ⤴

Correspondence

To be or not to be transgenic

Wayne A Parrott
Joseph M Jez
L Curtis Hannah
Correspondence 10 Sept 2012
Broad consent in biobanking

Chris Hempel
Geoffrey Lomax
Steve Peckman
Correspondence 10 Sept 2012
An accelerated workflow for untargeted metabolomics using the METLIN database

Ralf Tautenhahn
Kevin Cho
Gary Siuzdak
Correspondence 10 Sept 2012
Successful suppression of a field mosquito population by sustained release of engineered male mosquitoes

Angela F Harris
Andrew R McKemey
Luke Alphey
Correspondence 10 Sept 2012

Top of page ⤴

Patents

Teva v. AstraZeneca and secret prior art under 102(g)(2)

A recent Federal Circuit decision and the reasoning behind it could have a significant impact on the patentability of other life science inventions, even after changes in the patent law.

Sandra Lee
Michael Knierim
Patents 10 Sept 2012
Recent patent applications in biosensors

Patents 10 Sept 2012

Top of page ⤴

News & Views

Modulating WNT receptor turnover for tissue repair

New mechanistic insight into the regulation of WNT signaling supports efforts to target this pathway in adult stem cells for regenerative medicine.

Arie Abo
Hans Clevers
News & Views 10 Sept 2012
RNA-mediated programmable DNA cleavage

Genome engineering has a new tool—endonucleases involved in bacterial adaptive immunity that can be reprogrammed with customizable small, noncoding RNAs.

Rodolphe Barrangou
News & Views 10 Sept 2012
Silicon dreams of cells into symbols

Diverse mathematical models combine to create a comprehensive whole-cell computational model of a human pathogen.

Jeremy Gunawardena
News & Views 10 Sept 2012

Top of page ⤴

Research Highlights

High-speed imaging in a flow

Markus Elsner
Research Highlights 10 Sept 2012
Membrane fishing for HIV-neutralizing antibodies

Christine Borowski
Research Highlights 10 Sept 2012
Expanding the engineer's toolkit

Susan Jones
Research Highlights 10 Sept 2012
Photoactive chemical 'restores' sight

Laura DeFrancesco
Research Highlights 10 Sept 2012
mRNA-bound proteome

Markus Elsner
Research Highlights 10 Sept 2012

Top of page ⤴

Perspective

Navigating cancer network attractors for tumor-specific therapy

Pau Creixell
Erwin M Schoof
Rune Linding
Perspective 10 Sept 2012
Lessons from human teratomas to guide development of safe stem cell therapies

Justine J Cunningham
Thomas M Ulbright
Leendert H J Looijenga
Perspective 10 Sept 2012

Top of page ⤴

Article

Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators

Mass cytometry can measure up to 34 markers on cells, but samples cannot be multiplexed. Bodenmiller et al. use metal ion tags to facilitate multiplexed mass cytometry analysis of human blood cell samples treated with 27 kinase inhibitors and 12 stimuli across a range of dosages and time points.

Bernd Bodenmiller
Eli R Zunder
Garry P Nolan
Article 19 Aug 2012
Combinatorial discovery of polymers resistant to bacterial attachment

Bacterial attachment and biofilm formation are problematic for medical devices. Hook et al. present a high-throughput method to find materials that resist bacterial attachment and colonization.

Andrew L Hook
Chien-Yi Chang
Morgan R Alexander
Article 12 Aug 2012

Top of page ⤴

Letter

Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein

Wong et al. differentiate human pluripotent stem cells into mature airway epithelial cells expressing CFTR, a gene involved in cystic fibrosis. Applying the method to induced pluripotent stem cells derived from cystic fibrosis patients provides a renewable source of cells for drug screening.

Amy P Wong
Christine E Bear
Janet Rossant
Letter 26 Aug 2012
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens

No mucosal adjuvant formulation is approved for clinical use, even though boosting immunity at sites of pathogen entry should increase the efficacy of nonreplicating vaccines. Wegmann et al. report that polyethyleneimine (PEI) acts as a potent mucosal adjuvant for protein antigens from influenza and herpes simplex virus, protecting mice against otherwise lethal infections.

Frank Wegmann
Kate H Gartlan
Quentin J Sattentau
Letter 26 Aug 2012
Engineering phosphorus metabolism in plants to produce a dual fertilization and weed control system

López-Arredondo and Herrera-Estrella produce transgenic plants that express a bacterial phosphite-oxidoreductase gene to enable use of phosphite as a sole phosphorus source. This technology could reduce the amount of non-renewable phosphorus used as fertilizer and control weeds.

Damar Lizbeth López-Arredondo
Luis Herrera-Estrella
Letter 26 Aug 2012

Top of page ⤴

Careers and Recruitment

Theory to practice: real-world case-based learning for management degrees

For scientists looking to break into the biotech industry, scientific knowledge and technical skills are only a partial requirement for success.

Maria Theodosiou
Jean-Philippe Rennard
Arsia Amir-Aslani
Careers and Recruitment 10 Sept 2012
People

Careers and Recruitment 10 Sept 2012

Top of page ⤴

In This Issue

In this issue

In This Issue 10 Sept 2012

Top of page ⤴

Volume 30 Issue 9, September 2012

Editorial

News

Data Page

News Feature

Bioentrepreneur

Correspondence

Patents

News & Views

Research Highlights

Perspective

Article

Letter

Careers and Recruitment

In This Issue

Search

Quick links